Upadacitinib 30mg Demonstrates Superior Efficacy Among JAK Inhibitors for Atopic Dermatitis, While Safety Analysis Reveals New Infection Risks
核心洞察
Upadacitinib 30mg showed superior short-term efficacy compared to four other JAK inhibitors for moderate-to-severe atopic dermatitis (搜索), with odds ratios of 12.3 for EASI-75 response and 18.9 for clear/almost clear skin.
Real-world safety analysis of 1,326 adverse event reports identified previously unlabeled infection risks including sepsis (搜索), appendicitis (搜索), and septic shock associated with both upadacitinib and abrocitinib.
Herpes zoster (搜索) emerged as the most frequently reported infection-related adverse event for both JAK-1 (搜索) inhibitors, with upadacitinib showing higher rates of respiratory infections and abrocitinib more associated with cutaneous viral infections.
A comprehensive analysis of JAK inhibitors for atopic dermatitis (搜索) has revealed significant differences in both efficacy and safety profiles, with upadacitinib 30mg demonstrating superior therapeutic outcomes while real-world data uncovers previously unrecognized infection risks across the drug class.
Upadacitinib 30mg Leads Efficacy Rankings
A Bayesian network meta-analysis of nine randomized controlled trials involving 4,261 patients found upadacitinib 30mg consistently achieved the highest efficacy across all endpoints for moderate-to-severe atopic dermatitis (搜索). The study, led by Arya Babul from the West Career & Technical Academy (搜索), compared upadacitinib to abrocitinib (100 or 200 mg), baricitinib (2 or 4 mg), and ivarmacitinib (4 or 8 mg).
For the primary endpoint of at least 75% improvement in Eczema Area and Severity Index (EASI-75) at 12-16 weeks, upadacitinib 30mg achieved an odds ratio of 12.3 (95% credible interval, 7.9-18.7). The drug also demonstrated superior performance for Investigator's Global Assessment scores of clear or almost clear skin (IGA-AD 0/1), with an OR of 18.9 (95% CrI, 12.0-29.7).
Pruritus control, measured by at least a 4-point reduction in Itch Numeric Rating Scale scores, showed upadacitinib 30mg maintaining its lead with an OR of 11.1 (95% CrI, 7.2-17.5). Surface under the cumulative ranking curve (SUCRA) analyses confirmed these findings, with upadacitinib 30mg attaining probabilities ranging from 97-98% for being the most effective option across different endpoints.
The efficacy hierarchy placed upadacitinib 15mg second, followed by abrocitinib 200mg and ivarmacitinib 8mg. Baricitinib at both 2mg and 4mg doses consistently ranked lowest across all measures.
Real-World Safety Analysis Reveals Hidden Risks
A separate pharmacovigilance study analyzing the FDA Adverse Event Reporting System (FAERS) database from Q3 2019 to Q1 2025 identified concerning safety signals not adequately reflected in current drug labeling. The analysis examined 298 reports for abrocitinib and 1,028 reports for upadacitinib, focusing specifically on infection-related adverse events in atopic dermatitis (搜索) patients.
Using four different disproportionality analysis methods, researchers identified 18 positive infection signals for abrocitinib and 64 for upadacitinib. Most significantly, both drugs showed strong statistical associations with serious unlabeled adverse events including sepsis (搜索), appendicitis (搜索), and septic shock.
Herpes Zoster Dominates Infection Profile
Herpes zoster (搜索) emerged as the most frequently reported infection-related adverse event for both JAK-1 (搜索) inhibitors, confirming previous clinical trial findings. The analysis revealed 14 infection types common to both drugs, including herpes zoster, eczema herpeticum (搜索), and herpes simplex (搜索).
However, distinct patterns emerged between the two medications. Upadacitinib showed higher reporting rates for respiratory infections including pneumonia (搜索) and influenza, while abrocitinib demonstrated stronger associations with cutaneous viral infections, particularly eczema herpeticum (搜索) and herpes simplex (搜索) as the second most frequently reported adverse event.
The demographic analysis showed gender differences in adverse event reporting, with abrocitinib showing higher male predominance (55.4% vs. 39.9% female), while upadacitinib demonstrated more balanced gender distribution (48.2% vs. 45.2%). The majority of reports for both drugs originated from patients aged 18-65 years and were submitted from the United States.
Clinical Implications and Risk Management
The efficacy findings support upadacitinib's preferential consideration as a systemic JAK inhibitor for moderate-to-severe atopic dermatitis (搜索) unresponsive to biologic or topical therapies. However, the safety analysis underscores the need for enhanced vigilance regarding infection risks beyond those currently emphasized in product labeling.
Sepsis (搜索), with an estimated mortality rate of 30-40%, represents a particularly concerning unlabeled risk. The JAK-STAT pathway (搜索)'s complex role in sepsis pathogenesis may contribute to this association, though the precise mechanisms remain unclear. Clinicians should maintain high suspicion for systemic infections, particularly in high-risk patients such as the elderly or those with diabetes.
The identification of appendicitis (搜索) as an unlabeled adverse event raises additional concerns, as the anti-inflammatory properties of JAK inhibitors may mask classic symptoms, potentially delaying diagnosis and increasing perforation risk. New-onset abdominal pain during treatment warrants immediate clinical evaluation.
Monitoring and Prevention Strategies
The predominance of herpes zoster (搜索) infections across both medications highlights the importance of risk assessment and monitoring. Multiple factors contribute to increased susceptibility, including advanced age, female sex, Asian and Oceanian ethnicity, concomitant immunosuppressive drug use, and lifestyle factors such as smoking and psychological stress.
Recombinant herpes zoster (搜索) vaccines have demonstrated effectiveness in reducing incidence and severity, and vaccination should be considered for appropriate atopic dermatitis (搜索) patients receiving JAK inhibitors. Additionally, patients with histories of recurrent respiratory infections may benefit from prioritizing abrocitinib, while those with severe or frequent herpes viral infections require extreme caution with either medication.
The analysis excluded reports involving concomitant use of common atopic dermatitis (搜索) medications including topical corticosteroids, antihistamines, and dupilumab, yet still identified 15 positive signals with abrocitinib and 40 with upadacitinib, suggesting these infection risks persist even with monotherapy.
These findings emphasize the need for comprehensive baseline screening for active infections, regular monitoring during treatment, and patient education regarding infection warning signs. The balance between therapeutic efficacy and infection risk requires careful individualized assessment, particularly given the superior efficacy demonstrated by higher-dose upadacitinib.